Current position:Home > Selling > LGD-4033

LGD-4033

  • CAS No.: 1165910-22-4
  • Purity: 99%
  • Min quantity: 1000 Kilograms
  • Price: USD 1~2/Kilograms
  • Place of Orign: wuhan,Hubei,China
Ms.Merry Zhou

Supplier Details

View the Seller's Store
Product Details
Company Profile

Item specifics

Details

LGD-4033
Synonyms:4-((R)-2-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile(LGD-4033);LGD-4033;4-[(2R)-2-[(1R)-2,2,2-Trifluoro-1-hydroxyethyl]-1-pyrrolidinyl]-2-(trifluoromethyl)benzonitrile;4-((R)-2-((R)-2,2,2-Trifluoro-1-hydroxyethyl)pyrrolidin-1-yl)-2-trifluoroMethyl)benzonitrile
CAS:1165910-22-4
MF:C14H12F6N2O
MW:338.2482992
Usage:LGD-4033 (Ligandrol) is a selective oral androgen receptor modulator (SARM) that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It is in a class of androgen receptor (AR) ligands that are tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss.

LGD-4033 is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.

Name CAS NO. Usage
AICAR 2627-69-2 acts by entering nucleoside pools, significantly increasing levels of adenosine during periods of ATP breakdown
MK2866 841205-47-8 medical prescription for prevention of cachexia, atrophy, and sarcopenia and for Hormone or Testoserone Replacement Therapy.
MK-677 15972-10-0 A growth hormone secretagogue, treatment of obesity, a promising therapy for the treatment of frailty in the elderly
LGD-4033 1165910-22-4 pharmacological profile similar to that of enobosarm, Ostarine,MK-2866
GW1516 317318-70-0 For obesity, diabetes, dyslipidemia and cardiovascular disease
Andarine(S4) 401900-40-0 partial agonist, intended mainly for treatment of benign prostatic hypertrophy
SR9009 1379686-30-2 under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice
SR9011 1379686-30-2 For obesity, diabetes, dyslipidemia and cardiovascular disease
RAD140 1182367-47-0 New generation for gaining mass and cutting edges
YK11 366508-78-3 YK11: a SARM and myostatin inhibitor in one
431579-34-9
LGD-4033

Permanent link:

Send message to this supplier

Ms.Merry Zhou
View the Seller's Store
- Enter between 20 to 3,000 characters. English only.
Your message must be between 20-2000 characters.English only.

Look for similar items

  • Home > Pharmaceuticals and Biochemicals > Pharmaceutical